066 A Missed Therapeutic Opportunity? SGLT-2 Inhibitor use in General Medicine Patients With Heart Failure - A Retrospective Audit of Admissions to a Tertiary Health Service

Abstract

A total of 150 admissions fulfilled criteria. Baseline demographics and comorbidities identified an older, more comorbid population than reference trials. These included age (75% over 75 years), smoking history (46%), hypertension (83%), chronic kidney disease grade 4/5 (26%), previous myocardial infarction (57%), stroke (18%), atrial fibrillation (55%), and known left ventricular ejection fraction,50% (38%). Co-prescribed medications included ACE-I/ARB (53%), beta-blocker (67%), loop diuretic (87%), thiazide (7%), MRA (31%), insulin (57%), metformin (47%), sulfonylurea (31%), DPP-4 Inhibitor (21%), GLP-1 analogue (6%), and 15% of patients had an HbA1c.10. There was a significant difference between patients in our study eligible for and prescribed metformin (66/111) compared to SGLT-2 inhibitors (4/25) (p=0.013). A total of 26 patients had readmissions within 28 days, of which one had been discharged on an SGLT2-I. Conclusion: The results of this study identified significant under prescribing of SGLT2-I's in eligible type 2 diabetic patients with heart failure admitted under general medicine.